Literature DB >> 6370420

Relationship of tumor leucocytic infiltration to host defense mechanisms and prognosis.

J W Kreider, G L Bartlett, B L Butkiewicz.   

Abstract

The interface between the tumor and the host is often the site of leucocytic infiltration. We will examine the idea that the infiltrating leucocytes of human and experimental tumors are components of the host immunological defense against the tumor, and that the presence of the infiltrate is a marker of favorable prognosis. Leucocytes could infiltrate tumors because of an active immune response, either nonspecific or specifically directed to tumor-associated antigens. Leucocyte influx may also occur because of chemotactic factors secreted by the tumor cells. Some tumors release factors which enhance vascular permeability and permit improved access by leucocytes to the tumor focus. The consequences of leucocytic infiltration include tumor cell cytolysis, cytostasis, or stimulation of proliferation. The present state of our knowledge of the interactions between tumor cells and infiltrating leucocytes precludes broad generalization of mechanisms. Further study will probably reveal that the mechanisms are diverse, and that there are some systems in which immune interactions occur at this interface and others in which they do not.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6370420     DOI: 10.1007/bf00047693

Source DB:  PubMed          Journal:  Cancer Metastasis Rev        ISSN: 0167-7659            Impact factor:   9.264


  117 in total

1.  THE ROLE OF LYMPHOCYTES IN THE REJECTION OF CANINE RENAL HOMOTRANSPLANTS.

Authors:  K A PORTER; N H JOSEPH; J M RENDALL; C STOLINSKI; R J HOEHN; R Y CALNE
Journal:  Lab Invest       Date:  1964-09       Impact factor: 5.662

2.  Activated lymphocytes trigger lymphoblast extravasation.

Authors:  T W Jungi; D D McGregor
Journal:  Cell Immunol       Date:  1978-06       Impact factor: 4.868

3.  Lymphoid infiltrates in neuroblastomas: their occurrence and prognostic significance.

Authors:  R F Martin; J B Beckwith
Journal:  J Pediatr Surg       Date:  1968-02       Impact factor: 2.545

4.  Some biologic, immunogenic, and morphologic effects in mice after infection with a murine sarcoma virus. II. Morphologic studies.

Authors:  M F Stanton; L W Law; R C Ting
Journal:  J Natl Cancer Inst       Date:  1968-05       Impact factor: 13.506

5.  T-lymphocyte subsets and HLA-DR-expressing cells in rejected human kidney grafts.

Authors:  G Tufveson; U Forsum; K Claesson; L Klareskog; E Larsson; A Karlsson-Parra; L Frödin
Journal:  Scand J Immunol       Date:  1983-07       Impact factor: 3.487

6.  OKT3: a monoclonal anti-human T lymphocyte antibody with potent mitogenic properties.

Authors:  J P Van Wauwe; J R De Mey; J G Goossens
Journal:  J Immunol       Date:  1980-06       Impact factor: 5.422

7.  Fibrin gel investment associated with line 1 and line 10 solid tumor growth, angiogenesis, and fibroplasia in guinea pigs. Role of cellular immunity, myofibroblasts, microvascular damage, and infarction in line 1 tumor regression.

Authors:  H F Dvorak; A M Dvorak; E J Manseau; L Wiberg; W H Churchill
Journal:  J Natl Cancer Inst       Date:  1979-06       Impact factor: 13.506

8.  Cell proliferation in human melanoma.

Authors:  S Shirakawa; J K Luce; I Tannock; E Frei
Journal:  J Clin Invest       Date:  1970-06       Impact factor: 14.808

9.  Immunoperoxidase localization of lymphocyte subsets in the host response to melanoma and nevi.

Authors:  M J Kornstein; J S Brooks; D E Elder
Journal:  Cancer Res       Date:  1983-06       Impact factor: 12.701

10.  Redistribution of renal allograft-responding leukocytes during rejection. II. Kinetics and specificity.

Authors:  A Nemlander; A Soots; E von Willebrand; B Husberg; P Hayry
Journal:  J Exp Med       Date:  1982-10-01       Impact factor: 14.307

View more
  10 in total

Review 1.  Rationale for immunotherapy of renal cell carcinoma.

Authors:  R Heicappell; R Ackermann
Journal:  Urol Res       Date:  1990

Review 2.  Implications of tumor progression on clinical oncology.

Authors:  D R Welch; S P Tomasovic
Journal:  Clin Exp Metastasis       Date:  1985 Jul-Sep       Impact factor: 5.150

3.  Inducible heat shock protein 70 expression as a potential predictive marker of metastasis in breast tumors.

Authors:  Carolina Torronteguy; Antonio Frasson; Felipe Zerwes; Erik Winnikov; Vinicius Duval da Silva; Antoine Ménoret; Cristina Bonorino
Journal:  Cell Stress Chaperones       Date:  2006       Impact factor: 3.667

4.  Survival in rectal cancer is predicted by T cell infiltration of tumour-associated lymphoid nodules.

Authors:  T P W McMullen; R Lai; L Dabbagh; T M Wallace; C J de Gara
Journal:  Clin Exp Immunol       Date:  2010-04-09       Impact factor: 4.330

5.  A gelatin sponge model for studying tumor growth: quantitation of tumor cells and leukocytes in the CHO tumor.

Authors:  E T Akporiaye; G C Saunders; P M Kraemer
Journal:  Experientia       Date:  1987-06-15

6.  P-selectin deficiency attenuates tumor growth and metastasis.

Authors:  Y J Kim; L Borsig; N M Varki; A Varki
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-04       Impact factor: 11.205

7.  Characterization of fresh (uncultured) tumour-infiltrating lymphocytes (TIL) and TIL-derived T cell lines from patients with renal cell carcinoma.

Authors:  D Mitropoulos; S Kooi; J Rodriguez-Villanueva; C D Platsoucas
Journal:  Clin Exp Immunol       Date:  1994-08       Impact factor: 4.330

Review 8.  Human autologous tumor-specific T cells in malignant melanoma.

Authors:  C D Platsoucas
Journal:  Cancer Metastasis Rev       Date:  1991-06       Impact factor: 9.264

9.  Study of the relationship between immunohistologically demonstrated lymphocytes infiltrating human breast carcinomas and patients' survival.

Authors:  H O Wintzer; W Bohle; S von Kleist
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

Review 10.  The initial immune reaction to a new tumor antigen is always stimulatory and probably necessary for the tumor's growth.

Authors:  Richmond T Prehn
Journal:  Clin Dev Immunol       Date:  2010-07-27
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.